NQO1 and obesity disorder: In murine models of metabolic syndrome, β-lapachone-induced pharmacological activation of NADH oxidation by NQO1 showed the substantial improvement of metabolic syndrome and related phenotypes, including obesity, fatty liver, dyslipidemia, and glucose intolerance [1,101].